Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.38 |
| ▸ | NAMPT | P43490 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186663 | 0.92 | MAPK1 (0.37) | MAPK1TRPV1NAMPTMEN1KMT2A | |
| SCHEMBL186159 | 0.91 | CCR2 (0.41) | MAPK1MEN1KMT2A | |
| SCHEMBL300739 | 0.89 | CNR1 (0.45) | MAPK1NAMPTMEN1KMT2A | |
| SCHEMBL185941 | 0.88 | TRPV1 (0.40) | MAPK1TRPV1NAMPT | |
| SCHEMBL186594 | 0.84 | MEN1 (0.40) | MAPK1NAMPTMEN1KMT2A | |
| SCHEMBL2175479 | 0.84 | NAMPT (0.39) | MAPK1NAMPTMEN1KMT2A | |
| SCHEMBL186614 | 0.83 | PIM1 (0.40) | MAPK1TRPV1MEN1KMT2A | |
| SCHEMBL186206 | 0.83 | SLC6A7 (0.44) | MAPK1NAMPTMEN1KMT2A | |
| SCHEMBL18576998 | 0.82 | TRPV1 (0.40) | MAPK1TRPV1NAMPT | |
| SCHEMBL186245 | 0.82 | CCR2 (0.42) | MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193190-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI-AVENTIS (FR) | 2012-06-05 | — | — | US | claimed |
| EP-2297148-B8 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-03-28 | — | — | EP | claimed |
| EP-2297148-B1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-01-04 | — | — | EP | claimed |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| EP-2297148-A1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | Sanofi-Aventis (FR) | 2011-03-23 | — | — | EP | claimed |
| WO-2009150388-A1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | claimed |
| US-8519143-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI (FR) | 2013-08-27 | — | — | US | disclosed |
| US-20120232280-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2012-09-13 | — | — | US | disclosed |
| US-8193190-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI-AVENTIS (FR) | 2012-06-05 | — | — | US | disclosed |
| EP-2297148-B8 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-03-28 | — | — | EP | disclosed |
| EP-2297148-B1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-01-04 | — | — | EP | disclosed |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2297148-A1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | Sanofi-Aventis (FR) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009150388-A1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | MAPK1 981/4885TRPV1 1056/4885NAMPT 552/4885 |
| US-20120232280-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | MAPK1 981/4885TRPV1 1056/4885NAMPT 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.